Ticker

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting,…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome announces the publication of positive preclinical results in uveitis, addressing a $3B potential market opportunity.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (NASDAQ: HIND), a clinical-stage biopharmaceutical company focused on developing therapies for serious immuno-inflammatory and rare conditions, today announced that it has filed for Orphan Drug Status for VT-1953, its lead clinical program. Key anticipated benefits of an orphan drug designation include 7 years of U.S. market exclusivity, up to 25% of…